The Rate Of Blood Coagulation Is Determined Genetically.
In an crack to uncover why some people's blood platelets wood faster than others, a genetic breakdown has turned up a limited grouping of overactive genes that seems to put down the process. On the plus side, platelets are critical for fending off infections and healing wounds sildenafil online shop. On the down side, they can run hub disease, heart attacks and stroke, the study authors noted.
The trend finding regarding the genetic roots driving platelet behavior comes from what is believed to be the largest consider of the anthropoid genetic code to date, according to co-senior study investigator Dr Lewis Becker, a cardiologist with the Johns Hopkins University School of Medicine. "Our results give us a cleanly set of brand-new molecular targets, the proteins produced from these genes, to advance tests that could balm us identify people more at risk for blood clots and for whom absolute blood-thinning drugs may work best or not," Becker said in a Johns Hopkins item release.
So "We can even look toward testing renewed treatments that may speed up how the body fights infection or recovers from wounds," he added. The investigation findings were published online June 7 in Nature Genetics.
Showing posts with label platelet. Show all posts
Showing posts with label platelet. Show all posts
Tuesday, December 31, 2013
Thursday, August 22, 2013
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing resolution attacks, blood clots or extermination than the insigne disgrace prescribe in patients who had received artery-opening stents, new into or shows. The higher dose - magnify the usual amount - was tested in patients with "high platelet reactivity," sense they failed to respond to the drug at lower doses vimax. Plavix (clopidogrel) helps interdict clots from forming in patients who have ineffective platelet reactivity and who have had stents inserted to prop get blocked arteries.
But the new study "doesn't support" physicians using the higher, 150-milligram portion of Plavix after stenting, according to bookwork lead author Dr Matthew Price, who presented the findings Tuesday at the annual tryst of the American Heart Association in Chicago. So, the writing-room leaves an important question unanswered: How to use heart patients who don't respond well to Plavix? "It remains aleatory to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an substantial examination to have done but the key issues are that a significant arrangement of the patients remained with high platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an implication if the measure was doubled. "Platelet reactivity varies widely," noted Price, kingpin of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a exorbitant reactivity destroy is associated with poorer outcomes after angioplasty and/or stenting. But until now, a bury rise in the amount of Plavix "has not been tested in a large randomized clinical trial," he said.
Higher doses of the blood-thinner Plavix were no better at preventing resolution attacks, blood clots or extermination than the insigne disgrace prescribe in patients who had received artery-opening stents, new into or shows. The higher dose - magnify the usual amount - was tested in patients with "high platelet reactivity," sense they failed to respond to the drug at lower doses vimax. Plavix (clopidogrel) helps interdict clots from forming in patients who have ineffective platelet reactivity and who have had stents inserted to prop get blocked arteries.
But the new study "doesn't support" physicians using the higher, 150-milligram portion of Plavix after stenting, according to bookwork lead author Dr Matthew Price, who presented the findings Tuesday at the annual tryst of the American Heart Association in Chicago. So, the writing-room leaves an important question unanswered: How to use heart patients who don't respond well to Plavix? "It remains aleatory to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an substantial examination to have done but the key issues are that a significant arrangement of the patients remained with high platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an implication if the measure was doubled. "Platelet reactivity varies widely," noted Price, kingpin of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a exorbitant reactivity destroy is associated with poorer outcomes after angioplasty and/or stenting. But until now, a bury rise in the amount of Plavix "has not been tested in a large randomized clinical trial," he said.
Subscribe to:
Posts (Atom)